Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management of acute myeloid leukemia (AML). Using NGS, clonal evolution can be monitored as the sequencing technique will be able to pick up on new mutations in response to treatment. Dr Gibson states a downfall of its use being time as follow-ups are needed in order to monitor leukemic mutations in patients. Dr Gibson also touches upon the importance of minimal residual disease (MRD) analysis in combination with genomic techniques when monitoring patients with leukemic mutations. This was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX.